Bart Jacobs

2.1k total citations
59 papers, 1.4k citations indexed

About

Bart Jacobs is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Bart Jacobs has authored 59 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 16 papers in Molecular Biology. Recurrent topics in Bart Jacobs's work include Colorectal Cancer Treatments and Studies (32 papers), Cancer Treatment and Pharmacology (12 papers) and Lung Cancer Treatments and Mutations (9 papers). Bart Jacobs is often cited by papers focused on Colorectal Cancer Treatments and Studies (32 papers), Cancer Treatment and Pharmacology (12 papers) and Lung Cancer Treatments and Mutations (9 papers). Bart Jacobs collaborates with scholars based in Netherlands, Belgium and United Kingdom. Bart Jacobs's co-authors include Sabine Tejpar, Wendy De Roock, Bart Biesmans, Jef De Schutter, Eric Van Cutsem, Jos H. Beijnen, Jan H.M. Schellens, Hans Prenen, Bart Claes and Diether Lambrechts and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Bart Jacobs

57 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bart Jacobs Netherlands	18	1.0k	459	408	301	283	59	1.4k
Marie-Christine Étienne-Grimaldi France	27	1.3k 1.2×	508 1.1×	722 1.8×	343 1.1×	242 0.9×	82	1.9k
Laura W. Goff United States	21	1.0k 1.0×	432 0.9×	742 1.8×	326 1.1×	340 1.2×	77	2.0k
Francisco Javier Ramos Spain	15	625 0.6×	422 0.9×	771 1.9×	192 0.6×	172 0.6×	42	1.4k
Bradley G. Somer United States	16	808 0.8×	304 0.7×	412 1.0×	279 0.9×	192 0.7×	45	1.3k
Rastilav Bahleda France	18	586 0.6×	434 0.9×	514 1.3×	164 0.5×	151 0.5×	66	1.2k
Daniel Mulkerin United States	18	670 0.6×	229 0.5×	366 0.9×	89 0.3×	155 0.5×	79	1.2k
Jeremy Cetnar United States	14	905 0.9×	788 1.7×	372 0.9×	233 0.8×	89 0.3×	42	1.4k
Katharine Hazell Switzerland	12	491 0.5×	423 0.9×	904 2.2×	196 0.7×	137 0.5×	19	1.3k
Tiziana Pressiani Italy	19	735 0.7×	440 1.0×	353 0.9×	348 1.2×	335 1.2×	76	1.5k
Ingrid Garajová Italy	19	503 0.5×	218 0.5×	404 1.0×	359 1.2×	104 0.4×	82	1.0k

Countries citing papers authored by Bart Jacobs

Since Specialization

Citations

This map shows the geographic impact of Bart Jacobs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart Jacobs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart Jacobs more than expected).

Fields of papers citing papers by Bart Jacobs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart Jacobs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart Jacobs. The network helps show where Bart Jacobs may publish in the future.

Co-authorship network of co-authors of Bart Jacobs

This figure shows the co-authorship network connecting the top 25 collaborators of Bart Jacobs. A scholar is included among the top collaborators of Bart Jacobs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bart Jacobs. Bart Jacobs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Huitema, Alwin D. R., et al.. (2024). Prolonged in-use physicochemical and biological stability of nivolumab and pembrolizumab diluted in saline infusion bags and in partially used medication vials. Journal of Oncology Pharmacy Practice. 31(8). 1199–1209. 1 indexed citations

Jacobs, Bart, et al.. (2024). Impact of bariatric surgery on oral anticancer drugs: an analysis of real-world data. Cancer Chemotherapy and Pharmacology. 94(1). 25–34. 3 indexed citations

Jacobs, Bart, et al.. (2023). Product Validation and Stability Testing of Pharmacy Compounded Cholic Acid Capsules for Dutch Patients with Rare Bile Acid Synthesis Defects. Pharmaceutics. 15(3). 773–773. 1 indexed citations

Nuland, Merel van, Bart Jacobs, Vincent O. Dezentjé, et al.. (2023). Cortisol as Biomarker for CYP17-Inhibition is Associated with Therapy Outcome of Abiraterone Acetate. Pharmaceutical Research. 40(12). 3001–3010. 2 indexed citations

Ree, Martijn H. van der, Laura van Dussen, Bart Jacobs, et al.. (2022). Effectiveness and safety of mexiletine in patients at risk for (recurrent) ventricular arrhythmias: a systematic review. EP Europace. 24(11). 1809–1823. 15 indexed citations

Jacobs, Bart, et al.. (2021). Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics. Cancer Medicine. 10(14). 4781–4789. 6 indexed citations

Janssen, Julie M., Bart Jacobs, Ellen J. B. Derissen, et al.. (2021). Population Pharmacokinetics of Intracellular 5-Fluorouridine 5′-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine. The AAPS Journal. 23(1). 23–23. 4 indexed citations

Jacobs, Bart, et al.. (2021). Pharmacy Compounded Medicines for Patients With Rare Diseases: Lessons Learned From Chenodeoxycholic Acid and Cholic Acid. Frontiers in Pharmacology. 12. 758210–758210. 11 indexed citations

Seligmann, Jenny F., Faye Elliott, Susan D. Richman, et al.. (2020). Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel. Annals of Oncology. 31(8). 1021–1029. 12 indexed citations

10.

Jacobs, Bart, Dick Pluim, Hilde Rosing, et al.. (2020). Phase I pharmacological study of continuous chronomodulated capecitabine treatment. Pharmaceutical Research. 37(5). 89–89. 13 indexed citations

11.

Jacobs, Bart, Dick Pluim, Hilde Rosing, et al.. (2018). Phase I pharmacological study of continuous chronomodulated capecitabine treatment. Annals of Oncology. 29. viii662–viii663. 1 indexed citations

12.

Jacobs, Bart, Nikol Snoeren, Hilde Rosing, et al.. (2018). The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases. European Journal of Clinical Pharmacology. 74(6). 737–744. 6 indexed citations

13.

Meulendijks, Didier, Linda M. Henricks, André B. P. Kuilenburg, et al.. (2016). Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines. Cancer Chemotherapy and Pharmacology. 78(4). 875–880. 18 indexed citations

14.

Schreuer, Max, Geert Meersseman, Yanina Jansen, et al.. (2016). Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. Journal of Translational Medicine. 14(1). 95–95. 116 indexed citations

15.

Jacobs, Bart, Hilde Rosing, Dick Pluim, et al.. (2016). A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine. Cancer Chemotherapy and Pharmacology. 77(6). 1201–1207. 4 indexed citations

16.

Jacobs, Bart, Hilde Rosing, Niels de Vries, et al.. (2016). Development and validation of a rapid and sensitive UPLC–MS/MS method for determination of uracil and dihydrouracil in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 126. 75–82. 40 indexed citations

17.

Saridaki, Zenia, Joanne B. Weidhaas, Heinz‐Josef Lenz, et al.. (2014). A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy. Clinical Cancer Research. 20(17). 4499–4510. 52 indexed citations

18.

Pluim, Dick, et al.. (2013). Pharmacodynamic assay of thymidylate synthase activity in peripheral blood mononuclear cells. Analytical and Bioanalytical Chemistry. 405(8). 2495–2503. 6 indexed citations

19.

Prenen, Hans, Jef De Schutter, Bart Jacobs, et al.. (2009). PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer. Clinical Cancer Research. 15(9). 3184–3188. 241 indexed citations

20.

Troisi, Roberto, Bart Jacobs, Bruno Van Vlem, et al.. (2000). A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas–kidney transplants. Clinical Transplantation. 14(4). 340–344. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact